TrialBridgeNCT06959433
Lu-177 PSMA Treatment in Cell Renal Carcinoma
Not Yet Recruiting · Phase 3 · Ankara University · registry updated 2026-02-27
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Summary Renal Cell Carcinoma (RCC) consists of 2% of all malignencies. RCCs are generally divided to histopathological subtypes as clear cell and non-clear cell variants. Clear cell variant responsible for the 75-80% of all RCCs. It is reported that 20-30% of RCCs are metastatic at the diagnosis and 5 years survival is approximately is 10-20% in this group of patients. Moreover, 60% of patients who are not metastatic at the diagnosis, develop metastates within 2-3 years. 2nd and 3th line effective treatment option in metastatic RCCs patients has been a subject of interest. PSMA (protatate specific membrane antigen) with the other name glutamate carboxypeptidase, is a transmembrane protein and overexpresses in prostate adenocarcinomas and neoangiogenesis spots of endothelium of other several tumor types. It infronts as a target for theranostic consept for mainly prostate cancer in nuclear medicine. As a radionuclide treatment option, Lu-177 PSMA treatment is proved as safe and effective treatment option in castration resistant prostata cancer patients....
Inclusion
- Progression after at least 2 lines of systemic therapy or existence of a contraindication to systemic therapies
- At least 3 years of life expectancy
- ECOG performance status ≤ 2
- Ability to sign informed consent
Exclusion
- Not having received any systemic therapies
- History of a secondary malignancy
- ECOG performance status \> 2
- Any contraindication for radionuclide therapy (pregnancy, lactation, organ disfunction, metastatic lesions with a risk of compression
- Previous history of any radionuclide therapies
- Inability to sign informed consent